Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in carDiac sarcoid detection and therapy monitoring writing group

Journal of Nuclear Medicine

Volumn 58, Issue 8, 2017, Pages 1341-1353

  Chareonthaitawee, Panithaya ^a   Beanlands, Rob S ^b   Chen, Wengen ^c   Dorbala, Sharmila ^d   Miller, Edward J ^e   Murthy, Venkatesh L ^f   Birnie, David H ^b   Chen, Edward S ^g   Cooper, Leslie T ^h   Tung, Roderick H ⁱ   White, Eric S ^f,j   Borges Neto, Salvador ^k   Di Carli, Marcelo F ^d   Gropler, Robert J ^l   Ruddy, Terrence D ^b   Schindler, Thomas H ^g   Blankstein, Ron ^d   Bateman, T M ^m   Cerqueira, M D ^m   Dilsizian, V ^m   Heller, G V ^m   Moller, D R ^m   Osborne, M T ^m   Sadeghi, M M ^m   Soman, P ^m   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; HEPARIN; TECHNETIUM 99M; THALLIUM 201;

ARTICLE; ATRIOVENTRICULAR BLOCK; AUTOPSY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC SARCOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CELL INFILTRATION; CELLULAR DISTRIBUTION; COMPLETE HEART BLOCK; CORTICOSTEROID THERAPY; DIABETIC PATIENT; DIET RESTRICTION; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART PERFUSION; HEART SCINTISCANNING; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; IDIOPATHIC SUSTAINED VENTRICULAR TACHYCARDIA; IMAGE ACQUISITION; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGING AND DISPLAY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFLAMMATORY CELL; LIPID DIET; LOW CARBOHYDRATE DIET; LOW DRUG DOSE; MEDICAL CARE; MEDICAL SOCIETY; MONITORING; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PACEMAKER IMPLANTATION; PARTIAL THROMBOPLASTIN TIME; PERICARDIAL EFFUSION; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROLONGED FASTING; QUANTITATIVE ANALYSIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; THERAPY MONITORING; CARDIOMYOPATHY; COMPUTER ASSISTED DIAGNOSIS; CONSENSUS; DIAGNOSTIC IMAGING; DOCUMENTATION; EXPERT WITNESS; NUCLEAR MEDICINE; SARCOIDOSIS; TREATMENT OUTCOME;

CARDIOMYOPATHIES; CONSENSUS; DOCUMENTATION; EXPERT TESTIMONY; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; SARCOIDOSIS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 85026516917     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.196287     Document Type: Article

References (99)

1. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:19-27.
2. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc. 2016;13:67-71.
3. Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high prevalence of sarcoidosis in a representative U.S. metropolitan population. Respir Med. 2012;106:893-899.
4. Grunewald J, Spagnolo P, Wahlström J, Eklund A. Immunogenetics of diseasecausing inflammation in sarcoidosis. Clin Rev Allergy Immunol. 2015;49:19-35.
5. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. Am Rev Respir Dis. 1984;130:29-32.
6. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982: epidemiology and clinical picture. Sarcoidosis. 1990;7:50-57.
7. Rybicki BA, Major M, Popovich J, Maliank MJ. lannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
8. Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946-2013: a population-based study. Mayo Clin Proc. 2016;91:183-188.
9. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America: analysis based on health care use. Ann Am Thorac Soc. 2016;13:1244-1252.
10. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31:372-379.
11. Iwai K, Sekiguti M, Hosoda Y, et al. Racial differences in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26-31.
12. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211.
13. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501-511.
14. Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146:1064-1072.
15. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977.
16. Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9:e005001.
17. Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: a pathology-focused review. Arch Pathol Lab Med. 2010;134:1039-1046.
18. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104:571-577.
19. Fleming HA. Sarcoid heart disease. BrMed J (Clin Res Ed). 1986;292:1095-1096.
20. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455-469.
21. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. Am J Med. 1977;63:86-108.
22. Smedema J-P, Snoep G, van Kroonenburgh MPG, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128:30-35.
23. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010.
24. Uusimaa P, Ylitalo K, Anttonen O, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10:760-766.
25. Wyplosz B, Marijon E, Dougados J, Pouchot J. Sarcoidosis: an unusual cause of acute pericarditis. Acta Cardiol. 2010;65:83-84.
26. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336-346.
27. Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation. 2012;125:e344-e346.
28. Chiu C-Z, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143-146.
29. Diagnostic standard and guidelines for sarcoidosis [in Japanese]. Japanese J Sarcoidosis Other Granulomatous Disord 2007;27:89-102
30. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-1323.
31. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Eur Heart J. 2007;28:3076-3093.
32. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461-468.
33. Casella M, Pizzamiglio F, Dello Russo A, et al. Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol. 2015;8:625-632.
34. Liang JJ, Hebl VB, DeSimone CV, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2:466-473.
35. Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29:1015.e1-1015.e3.
36. Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. September 9, 2016 [Epub ahead of print].
37. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-248.
38. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology. 2000;94:193-199.
39. Le Guludec D,Menad F, Faraggi M,Weinmann P, Battesti J-P, Valeyre D.Myocardial sarcoidosis: clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106:1675-1682.
40. Surasi DS, Manapragada PP, Lloyd SG, Bhambhvani P. Role of multimodality imaging including thallium-201 myocardial perfusion imaging in the diagnosis and monitoring of treatment response in cardiac sarcoidosis. J Nucl Cardiol. 2014;21:849-852.
41. Futamatsu H, Suzuki J, Adachi S, et al. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging. 2006;22:443-448.
42. Momose M, Kadoya M, Koshikawa M, Matsushita T, Yamada A. Usefulness of 67Ga SPECT and integrated low-dose CT scanning (SPECT/CT) in the diagnosis of cardiac sarcoidosis. Ann Nucl Med. 2007;21:545-551.
43. Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest. 2004;126:1372-1376.
44. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107:330-334.
45. 18F-FDG. J Nucl Med. 2005;46:1522-1530.
46. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336.
47. Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9:e000867.
48. Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12:2488-2498.
49. 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538-1543.
50. 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166-174.
51. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008; 133:1426-1435.
52. Osborne MT, Hulten EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017;24:86-99.
53. Taegtmeyer H. Tracing cardiac metabolism in vivo: one substrate at a time. J Nucl Med. 2010;51(suppl 1):80S-87S.
54. 18F-fluorodeoxyglucose uptake in the heart. Acta Radiol. 2016;57:661-668.
55. 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR. 2008;190:W151-W156.
56. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926-936.
57. 18F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol. 2010;17:286-291.
58. 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging. J Nucl Med. 2014;55:1629-1635.
59. 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol. 2013;62:314-319.
60. 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563-568.
61. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7:531-533.
62. Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244-252.
63. 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:1108-1115.
64. 18FDG PET assessment of inflammatory or malignant myocardial disease. J Nucl Cardiol. March 25, 2016 [Epub ahead of print].
65. 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.
66. 18F-FDG uptake after calcium channel blocker administration: initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging. 2011;38:2018-2024.
67. Dilsizian V, Bacharach SL, Beanlands R, et al. ASNC imaging guidelines/ SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23:1187-1226.
68. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989-1998.
69. DiFilippo FP, Brunken RC. Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT? J Nucl Med. 2005;46:436-443.
70. Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925-939.
71. Waller AH, Blankstein R. Quantifying myocardial inflammation using F18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. J Nucl Cardiol. 2014;21:940-943.
72. Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017;24:413-424.
73. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357: 2153-2165.
74. Baughman RP, Teirstein A, Judson M, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-1889.
75. Simonen P, Lehtonen J, Kandolin R, et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015;116:1581-1585.
76. 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
77. Promteangtrong C, Salavati A, Cheng G, Torigian DA, Alavi A. The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients. Hell J Nucl Med. 2014;17:123-135.
78. Mañá J, Gamez C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. 2011;17:325-331.
79. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949-1953.
80. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141:154-162.
81. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034-1041.
82. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133-137.
83. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83:315-334.
84. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173-182.
85. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795-802.
86. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142:1268-1271.
87. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117-1122.
88. Zuber M, Defer G, Cesaro P, Degos JD. Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry. 1992;55:166-167.
89. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155:1665-1669.
90. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307-315.
91. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72:337-340.
92. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937-943.
93. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738.
94. 18F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging. 2013;6:617-626.
95. 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801-810.
96. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219-1228.
97. 18F-FDG PET. J Nucl Med. 2003;44:1030-1036.
98. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933-941.
99. Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2015;16:949-958.